| Active substance | Inavolisib |
| Holder | Roche |
| Status | Running |
| Indication | Treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer (LA/mBC) following recurrence on or within 12 months of completing adjuvant endocrine treatment. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 09/03/2026 |